Interventional Glaucoma

Roundtable discussion explores surgical and sustained-release options.

Inder Paul Singh, MD, shares a formative experience in which a patient’s vision loss—and their unexpected gesture of comfort—shaped his approach to high-risk glaucoma care.

Bedrood describes improved visualization of the ciliary body, efficient setup, and favorable postoperative outcomes.

Innovations in selective laser trabeculoplasty and laser cyclophotocoagulation focus on procedural efficiency, patient comfort, and evolving first-line treatment strategies.

In this murine model of glaucoma, SPG302 was administered daily to 3-month-old mice for 8 weeks.

Explore groundbreaking advancements in eye care from the 2000s, including LASIK innovations, anti-VEGF treatments, and enhanced imaging technologies.

The VisiPlate aqueous shunt is made of a patented metamaterial that has been designed to be non-fibrotic and is many times thinner than a human hair, according to the company.

Explore the groundbreaking advancements in ophthalmic technology from the 1980s and 1990s, including excimer lasers, LASIK, and innovative imaging techniques.

From lasers to lenses, the 1970s redefined vision care through breakthroughs in surgery, imaging, and therapeutics.

Lupin notes that the acquisition will help to strengthen the company by “integrating VISUfarma’s established commercial operations.”

Smith highlights advances in interventional glaucoma, including first-line SLT, emerging surgical options, and co-management strategies, during the Ophthalmology Times and Optometry Times EyeCon 2025 conference.

Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and is the generic equivalent of LUMIGAN.

Potential loss to follow-up is a critical issue for these patients with glaucoma.

We ask leading experts in the field what eye disease they would cure and why.

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

Travoprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

This update from UHC includes procedures enabled with its OMNI Surgical System technology from Sight Sciences.

A study reveals Hispanic patients face lower success rates in trabeculectomy with MMC compared to European patients, highlighting significant disparities in glaucoma surgery outcomes.

Dr. Tanna will kick off the new monthly subspecialty education series with a virtual session on September 9, 2025, focused on using OCT imaging and perimetry to track glaucoma progression.

Surgical tools improve Schlemm canal access and enable earlier glaucoma care.

The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma.

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care, latanoprost 0.005%.

Extend the summer at EyeCon 2025—where clinical insight meets coastal vibes—September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida.